Literature DB >> 2006120

Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma.

P Ekman1, J Brolin.   

Abstract

The steroid receptor profile in seven prostate cancer metastases was compared with the profile in seven primary prostate cancers. The secondaries were all lymph node metastases, obtained during pelvic lymphadenectomy, preceding radical prostatectomy or irradiation. Cytosol androgen receptor content was higher in metastases, whereas the nuclear androgen receptor content was only one-fourth that in primary cancer. Cytosol progesterone as well as estrogen receptor contents were markedly lower in metastases compared with primary cancer. The steroid receptor profile differed very little between primary cancer and normal tissue. Primary prostatic carcinoma is usually obtained at early stages of the disease, whereas metastases represent a dedifferentiated, more aggressive cell population. This may explain the low amounts of progesterone, estrogen, and nuclear androgen receptor levels. The total androgen receptor content was similar in metastatic and primary disease, however, with a shift towards a cytosolic predominance in metastases. Possibly androgen receptors in metastatic disease are "deactivated."

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006120     DOI: 10.1002/pros.2990180207

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  Steroid receptor profile and receptor stability in subfractions of human prostatic tissues. Critical aspects on microassays.

Authors:  J Brolin; L Andersson; P Ekman
Journal:  Urol Res       Date:  1991

2.  Microassays for androgen and progesterone receptor quantitation as compared with standard saturation analyses in human prostatic tissues.

Authors:  J Brolin; P Ekman
Journal:  Urol Res       Date:  1991

3.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.